The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses

• Autores principales: Yuanxun Yang (Autor), Lei Yu (Autor), Zejuan Sheng (Autor), Hui Lin (Autor), Zuyi Weng (Autor), Wei Song (Autor), Bei Cao (Autor), Yu Zhao (Autor), Yingsheng Gao (Autor), Shumao Ni (Autor), Huimin Wang (Autor), Tingting Ma (Autor), Lei Huang (Autor), Caixia Sun (Autor), Juan Li (Autor)
• Formato: Libro
• Publicado: Frontiers Media S.A., 2024-04-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Introduction: TT-01025-CL is an oral, irreversible small molecule that potently inhibits vascular adhesion protein-1 (VAP-1) for the treatment of inflammation associated with non-alcoholic steatohepatitis (NASH). The objectives of this study were to evaluate the safety/tolerability, pharmacokinetics...